Regorafenib in Combination With Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed MGMT-Methylated, IDH Wild-type Glioblastoma. A Phase I Dose-finding Study
Latest Information Update: 27 Dec 2024
At a glance
- Drugs Regorafenib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- Acronyms REGOMA-2
- 24 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Feb 2024 New trial record